Thus, it remains possible that livmoniplimab would exhibit clinical activity beyond solid tumors, particularly in hematologic cancers with elevated GARP-expressing Tregs. This evidence concerns the gene LRRC32 and hematopoietic and lymphoid cell neoplasm.